Skip to main content
Top
Published in: Rheumatology International 5/2003

01-09-2003 | Original Article

Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters

Authors: Luigi Caserta, Laura de Magistris, Mario Secondulfo, Giancarlo Caravelli, Gabriele Riegler, Giovanna Cuomo, Salvatore D'Angelo, Caterina Naclerio, Gabriele Valentini, Romano Carratù

Published in: Rheumatology International | Issue 5/2003

Login to get access

Abstract

Objective

The aim of this study was to assess intestinal permeability (IP) in patients with systemic sclerosis (SSc) and to relate the results with general disease activity and gastrointestinal involvement.

Methods

Twenty-eight females and four males were studied. Patients with severe gastrointestinal involvement were excluded. Thirty-three healthy volunteers served as controls. Intestinal permeability was assessed by means of the orally administered cellobiose/mannitol sugar (Ce/Ma) test. Intestinal transit time (ITT) was investigated with the H2-lactulose breath test.

Results

The mean value of IP in 32 SSc patients was significantly higher than in 33 controls (P<0.05), although it fell within the normal range. Eleven patients showed abnormally high individual IP values (>0.028) that significantly correlated to disease duration (r=0.73). Altered IP was associated with the higher but not statistically relevant presence of anti-Scl70 antibodies (9/11) and to more severe gastrointestinal involvement. More than half of the SSc patients showed slower orocecal transit times on the H2 breath test. In particular, delayed ITT was observed in 60% of patients with increased IP and in all patients with moderate gastrointestinal involvement according to the scleroderma severity scale.

Conclusion

Intestinal permeability was altered in 11/32 SSc patients. Correlations between increased IP and duration of disease and degree of gastgrointestinal involvement appear to support the hypothesis of secondary involvement of the intestinal barrier, and the presence of anti-Scl70 antibodies in 82% of the patients with higher IP clearly reinforces the hypothesis of an altered immune response in these subjects.
Literature
1.
go back to reference Medsger TA Jr (1997) Systemic sclerosis (scleroderma): Clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions. A textbook of rheumatology, 13th edn. Williams and Wilkens, Baltimore, pp 1473–1479 Medsger TA Jr (1997) Systemic sclerosis (scleroderma): Clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions. A textbook of rheumatology, 13th edn. Williams and Wilkens, Baltimore, pp 1473–1479
2.
go back to reference Marie I, Levesque H, Ducrotte P, Courtois H (1999) Involvement of the small intestine in systemic scleroderma. Rev Med Interne 20:504–513CrossRefPubMed Marie I, Levesque H, Ducrotte P, Courtois H (1999) Involvement of the small intestine in systemic scleroderma. Rev Med Interne 20:504–513CrossRefPubMed
3.
go back to reference Folwaczny C, Rothfuss U, Riepl RL, Lehnert P, Bloching H, Meurer M, Karbach U (1995) Gastrointestinal involvement in progressive systemic scleroderma. Z Gastroenterol 33 11:654–661 Folwaczny C, Rothfuss U, Riepl RL, Lehnert P, Bloching H, Meurer M, Karbach U (1995) Gastrointestinal involvement in progressive systemic scleroderma. Z Gastroenterol 33 11:654–661
4.
go back to reference Marguerie C, Kaye S, Vyse T, Mackworth-Young C, Walport MJ, Black C (1995) Malabsorption caused by coeliac disease in patients who have scleroderma. Br J Rheumatol 34:858–861 Marguerie C, Kaye S, Vyse T, Mackworth-Young C, Walport MJ, Black C (1995) Malabsorption caused by coeliac disease in patients who have scleroderma. Br J Rheumatol 34:858–861
5.
go back to reference Serrander R, Magnusson KE, Kihlstrom E, Sundqvist T (1989) Acute Yersinia infections in man increase intestinal permeability for low molecular weight polyethylene glicols (PEG 400). Scand J Infect Dis 18:409–413 Serrander R, Magnusson KE, Kihlstrom E, Sundqvist T (1989) Acute Yersinia infections in man increase intestinal permeability for low molecular weight polyethylene glicols (PEG 400). Scand J Infect Dis 18:409–413
6.
go back to reference Lahesma-Rantala R, Magnusson KE, Gransfors K, Leino R, Sundqvist T, Toivanen A (1991) Intestinal permeability in patients with Yersinia triggered reactive arthritis. Ann Rheum Dis 50:91–94PubMed Lahesma-Rantala R, Magnusson KE, Gransfors K, Leino R, Sundqvist T, Toivanen A (1991) Intestinal permeability in patients with Yersinia triggered reactive arthritis. Ann Rheum Dis 50:91–94PubMed
7.
go back to reference Mielants H, Veys EM, Goemare S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMed Mielants H, Veys EM, Goemare S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMed
8.
go back to reference Mielants H, De Vos M, Goemare S, Schelstraete K, Cuvelier C, Goethals K, Maertens M, Ackerman C, Veys EM (1991) Intestinal mucosal permeability in inflammatory rheumatic disease. II. Role of disease. J Rheumatol 18:394–400PubMed Mielants H, De Vos M, Goemare S, Schelstraete K, Cuvelier C, Goethals K, Maertens M, Ackerman C, Veys EM (1991) Intestinal mucosal permeability in inflammatory rheumatic disease. II. Role of disease. J Rheumatol 18:394–400PubMed
9.
go back to reference Cobden I, Rothwell J, Axon ATR, Dixon MF, Lintott DJ, Rowell NR (1980) Small intestinal structure and passive permeability in systemic sclerosis. Gut 21:293–298PubMed Cobden I, Rothwell J, Axon ATR, Dixon MF, Lintott DJ, Rowell NR (1980) Small intestinal structure and passive permeability in systemic sclerosis. Gut 21:293–298PubMed
10.
go back to reference Catanoso M, Lo Gullo R, Giofre MR, Pallio S, Tortora A, Lo Presti M, Frisina N, Bagnato G, Fries W (2001) Gastrointestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheumatol 30:77–81CrossRefPubMed Catanoso M, Lo Gullo R, Giofre MR, Pallio S, Tortora A, Lo Presti M, Frisina N, Bagnato G, Fries W (2001) Gastrointestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheumatol 30:77–81CrossRefPubMed
11.
go back to reference Masi T (1985) Classification of systemic sclerosis (scleroderma). In: Black CM, Myers AR (eds) Current topics in rheumatology: systemic sclerosis (scleroderma). Gower, New York, pp 7–15 Masi T (1985) Classification of systemic sclerosis (scleroderma). In: Black CM, Myers AR (eds) Current topics in rheumatology: systemic sclerosis (scleroderma). Gower, New York, pp 7–15
12.
go back to reference Medsger TA Jr (2000) Assessment of damage and activity in systemic sclerosis. Curr Op Rheumatol 12:545–548CrossRef Medsger TA Jr (2000) Assessment of damage and activity in systemic sclerosis. Curr Op Rheumatol 12:545–548CrossRef
13.
go back to reference Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed
14.
go back to reference Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M (1986) Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13:911–916PubMed Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M (1986) Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13:911–916PubMed
15.
go back to reference Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G, Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc) (2002) Systemic sclerosis: demography, clinical and serological features and survival in 1012 Italian patients. Medicine (Baltimore) 81:139–153 Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G, Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc) (2002) Systemic sclerosis: demography, clinical and serological features and survival in 1012 Italian patients. Medicine (Baltimore) 81:139–153
16.
go back to reference Juby LD, Rothwell J, Axon ATR (1989) Cellobiose/mannitol sugar test—a sensitive tubeless test for coeliac disease: results on 1010 unselected patients. Gut 30:476–480PubMed Juby LD, Rothwell J, Axon ATR (1989) Cellobiose/mannitol sugar test—a sensitive tubeless test for coeliac disease: results on 1010 unselected patients. Gut 30:476–480PubMed
17.
go back to reference Hollander D (1993) The Intestinal permeability barrier. Scand J Gastroentrol 27:721–726 Hollander D (1993) The Intestinal permeability barrier. Scand J Gastroentrol 27:721–726
18.
go back to reference Troncone R, Mayer M, Mugione P, Cucciardi M, Abete A, Greco L (1995) Cellobiose/mannitol sugar permeability test in children in relation to jejunal morphometry. Ital J Gastroenterol 27:489–493PubMed Troncone R, Mayer M, Mugione P, Cucciardi M, Abete A, Greco L (1995) Cellobiose/mannitol sugar permeability test in children in relation to jejunal morphometry. Ital J Gastroenterol 27:489–493PubMed
19.
go back to reference Strobel S, Brydon WG, Ferguson A (1984) Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. Gut 25:1241–1246PubMed Strobel S, Brydon WG, Ferguson A (1984) Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. Gut 25:1241–1246PubMed
20.
go back to reference Corcoran AC, Page JH (1947) A method for the determination of mannitol in plasma and urine. J Biol Chem 170:165–171 Corcoran AC, Page JH (1947) A method for the determination of mannitol in plasma and urine. J Biol Chem 170:165–171
21.
go back to reference deMagistris L, Secondulfo M, Iafusco D, Carbone AG, Urio A, Pontoni G, Carratù R (1996) Altered mannitol absorption in diabetic children. Ital J Gastroenterol 28:367PubMed deMagistris L, Secondulfo M, Iafusco D, Carbone AG, Urio A, Pontoni G, Carratù R (1996) Altered mannitol absorption in diabetic children. Ital J Gastroenterol 28:367PubMed
22.
go back to reference Carratù R, Secondulfo M, deMagistris L, Daniele B, Pignata S, D'Agostino L, Frezza P, Elmo M, Silvestro G, Sasso FS (1998) Assessment of damage to small intestine in women treated with pelvic radiotherapy. Oncology Reports 5:635–639PubMed Carratù R, Secondulfo M, deMagistris L, Daniele B, Pignata S, D'Agostino L, Frezza P, Elmo M, Silvestro G, Sasso FS (1998) Assessment of damage to small intestine in women treated with pelvic radiotherapy. Oncology Reports 5:635–639PubMed
23.
go back to reference Carratù R, Secondulfo M, deMagistris L, Iafusco D, Urio A, Carbone AG, Pontoni G, Carteni M, Prisco F (1999) Altered intestinal permeability to mannitol in diabetes mellitus type I. J Ped Gastroenterol Nutr 28:264–269CrossRef Carratù R, Secondulfo M, deMagistris L, Iafusco D, Urio A, Carbone AG, Pontoni G, Carteni M, Prisco F (1999) Altered intestinal permeability to mannitol in diabetes mellitus type I. J Ped Gastroenterol Nutr 28:264–269CrossRef
24.
go back to reference Secondulfo M, deMagistris L, Fiandra R, Caserta L, Belletta M, Tartaglione MT, Riegler G, Biagi F, Corazza GR, Carratù R (2001) Intestinal permeability in Crohn's disease patients and their first degree relatives. Dig Liver Dis 33:680–685PubMed Secondulfo M, deMagistris L, Fiandra R, Caserta L, Belletta M, Tartaglione MT, Riegler G, Biagi F, Corazza GR, Carratù R (2001) Intestinal permeability in Crohn's disease patients and their first degree relatives. Dig Liver Dis 33:680–685PubMed
25.
go back to reference Daniele B, Secondulfo M, De Vivo R, Pignata S, deMagistris L, Delrio P, Palaia R, Barletta E, Tambaro R, Carratù R (2001) Effect of chemoterapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol 32:228–230CrossRefPubMed Daniele B, Secondulfo M, De Vivo R, Pignata S, deMagistris L, Delrio P, Palaia R, Barletta E, Tambaro R, Carratù R (2001) Effect of chemoterapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol 32:228–230CrossRefPubMed
26.
go back to reference M Secondulfo, L de Magistris, Carratù R (2002). How correct investigate intestinal permeability. Dig Liver Dis 34:533–534PubMed M Secondulfo, L de Magistris, Carratù R (2002). How correct investigate intestinal permeability. Dig Liver Dis 34:533–534PubMed
27.
go back to reference Bond JH Jr, Levitt MD, Prentiss R. (1975) Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med 85:546–555PubMed Bond JH Jr, Levitt MD, Prentiss R. (1975) Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med 85:546–555PubMed
28.
go back to reference Hollander D (2000) Intestinal permeability in health and disease. In: Kirsner JB (ed) Inflammatory bowel disease, fifth edn. Saunders, Philadelphia, pp 45–54 Hollander D (2000) Intestinal permeability in health and disease. In: Kirsner JB (ed) Inflammatory bowel disease, fifth edn. Saunders, Philadelphia, pp 45–54
Metadata
Title
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters
Authors
Luigi Caserta
Laura de Magistris
Mario Secondulfo
Giancarlo Caravelli
Gabriele Riegler
Giovanna Cuomo
Salvatore D'Angelo
Caterina Naclerio
Gabriele Valentini
Romano Carratù
Publication date
01-09-2003
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2003
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-003-0286-3

Other articles of this Issue 5/2003

Rheumatology International 5/2003 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.